Research programme: glucokinase stimulants - Hua Medicine/Roche

Drug Profile

Research programme: glucokinase stimulants - Hua Medicine/Roche

Alternative Names: GKA programme - Hua Medicine/Roche; Glucokinase activator programme - Hua Medicine/Roche; RO 0281675

Latest Information Update: 30 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Hua Medicine; Roche
  • Class Acrylamides; Small molecules
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 30 Oct 2013 No development reported - Preclinical for Type-2 diabetes mellitus in USA (PO)
  • 20 Dec 2011 Roche's glucokinase activator programme licensed to Hua Medicine worldwide, including the lead candidate RO 5305552
  • 01 Oct 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top